Quest Diagnostics Incorporated · NYSE (us_market)
Healthcare · Diagnostics & Research · United States
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2023-07-25$144.92 RISE2023-10-12$120.62 PEAK2024-01-09$142.11 168d | -16.8% 79d | Missed | Missed | — | — | +17.8% 89d | Missed |
DROP2022-05-27$145.39 RISE2022-09-21$121.77 PEAK2022-12-01$152.61 188d | -16.2% 117d | Missed | Missed | — | — | +25.3% 71d | Missed |
DROP2020-08-03$130.01 RISE2020-09-09$107.05 PEAK2020-11-05$128.05 94d | -17.7% 37d | Missed | Missed | — | — | +19.6% 57d | Missed |
DROP2020-03-05$115.68 RISE2020-04-03$73.34 PEAK2020-06-02$122.61 89d | -36.6% 29d | 2020-03-26 $88.97 | 2020-06-02 $122.61 | 65Deep Value | 46Deep Value | +67.2% 60d | +37.8% Held 68d |
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Since November 2025, Quest has been in a holding pattern, posting a small return of 2.6% while floating around $194.06. The stock also fell short of the S&P 500’s 9.8% gain during that period.
Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Quest Diagnostics is keeping analysts reasonably upbeat as steady execution and momentum continue supporting Wall Street confidence.
Quest Diagnostics is keeping analysts reasonably upbeat as steady execution and momentum continue supporting Wall Street confidence.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALGN expands Invisalign worldwide and iTero Lumina leads scanner mix, backed by $1.06B cash, yet 2026 ASP expected down 1-2%.
ALGN expands Invisalign worldwide and iTero Lumina leads scanner mix, backed by $1.06B cash, yet 2026 ASP expected down 1-2%.
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record of Quest Diagnostics common stock on July 8, 2026.
Quest Diagnostics gains from DIS growth, advanced diagnostics uptake and AI-driven efficiencies, though debt levels and healthcare reimbursement risks remain concerns.
Quest Diagnostics gains from DIS growth, advanced diagnostics uptake and AI-driven efficiencies, though debt levels and healthcare reimbursement risks remain concerns.
OURA, at the center of the tracking of the health and wellness boom, ranks No. 14 on CNBC’s 2026 Disruptor 50 list.
Discover how Quest Diagnostics (DGX) offers a sustainable 1.83% yield with strong profitability and health ratings, avoiding yield traps for reliable dividend growth.
Quest Diagnostics is in focus after a refreshed fair value estimate of US$223.25, up from US$218.19, modestly lifts the modeled price target. That change lines up with recent Street research where many firms are tweaking targets, with some leaning more optimistic and others emphasizing risk and near term execution. As you read on, you will see how these shifting targets shape the evolving analyst narrative and what to watch next. Analyst Price Targets don't always capture the full story. Head...
Quest Diagnostics is in focus after a refreshed fair value estimate of US$223.25, up from US$218.19, modestly lifts the modeled price target. That change lines up with recent Street research where many firms are tweaking targets, with some leaning more optimistic and others emphasizing risk and near term execution. As you read on, you will see how these shifting targets shape the evolving analyst narrative and what to watch next. Analyst Price Targets don't always capture the full story. Head...
Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.
Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| DGX | +1.16% | -7.30% | +12.31% | +12.44% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -1.81% | -1.59% | +15.76% | -0.25% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 5.38M | $1.05B | 0.04% | Unchanged | 2026-03-31 |
| FidelityFMR | fundamental | 942.2K | $184.66M | 0.01% | Trimmed-21.6% | 2026-03-31 |
| DEShaw | quant | 147.7K | $28.95M | 0.02% | Trimmed-55.1% | 2026-03-31 |
| Wellington | fundamental | 90.7K | $17.78M | 0.00% | Trimmed-9.4% | 2026-03-31 |
| TRowePrice | fundamental | 6.30M | $1.23M | 0.14% | Unchanged | 2026-03-31 |
| Bridgewater | macro | 3.5K | $680.25K | 0.00% | Trimmed-1.3% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | PFEIFFER GARY M | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-05-21 | MORRISON DENISE M | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-05-21 | Lassiter Wright III | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-05-21 | RING TIMOTHY M | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-05-21 | Doi Tracey | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-05-21 | WENTWORTH TIMOTHY C | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-05-21 | MAIN TIMOTHY L | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-05-21 | Diaz Luis | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-05-21 | Gregg Vicky B | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-05-21 | CARTER ROBERT B | Director | A Grant / award | 1,142 | — | +$0 |
| 2026-04-24 | DELANEY MARK E | SVP & Chief Commercial Officer | L L | 37 | $194.70 | +$7.2K |
| 2026-04-24 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L L | 39 | $194.70 | +$7.6K |
| 2026-04-24 | Lassiter Wright III | Director | L L | 6 | $194.70 | +$1.2K |
| 2026-04-24 | CARTER ROBERT B | Director | L L | 7 | $194.70 | +$1.4K |
| 2026-04-24 | Gregg Vicky B | Director | A Grant / award | 68 | $194.70 | +$13.2K |
| 2026-04-24 | Plewman Patrick | SVP for Diagnostic Services | L L | 49 | $194.70 | +$9.5K |
| 2026-04-24 | SAMAD SAM | Executive Vice President & CFO | A Grant / award | 108 | $194.70 | +$21.0K |
| 2026-04-02 | WENTWORTH TIMOTHY C | Director | A Grant / award(deriv) | 198 | — | +$0 |
| 2026-03-11 | WENTWORTH TIMOTHY C | Director | A Grant / award | 215 | — | +$0 |
| 2026-03-06 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S Open-market sale | 2,628 | $204.86 | −$538.4K |
| 2026-03-06 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A Grant / award | 6,200 | $204.86 | +$1.27M |
| 2026-03-06 | Deppe Michael J | SVP, Corp. Controller & CAO | F Tax withholding | 750 | $204.86 | −$153.6K |
| 2026-03-06 | Deppe Michael J | SVP, Corp. Controller & CAO | A Grant / award | 1,473 | $204.86 | +$301.8K |
| 2026-03-06 | Plewman Patrick | SVP for Diagnostic Services | S Open-market sale | 2,855 | $206.21 | −$588.7K |
| 2026-03-06 | Plewman Patrick | SVP for Diagnostic Services | F Tax withholding | 2,827 | $204.86 | −$579.1K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-21upcoming | 2.82 | — | — |
| 2026-04-21 | 2.37 | 2.50 | +5.61% |
| 2026-02-10 | 2.36 | 2.42 | +2.63% |
| 2025-10-21 | 2.50 | 2.60 | +3.85% |
| 2025-07-22 | 2.32 | 2.47 | +6.28% |
| 2025-04-22 | 2.15 | 2.21 | +2.78% |
| 2025-01-30 | 2.18 | 2.23 | +2.09% |
| 2024-10-22 | 2.26 | 2.30 | +1.90% |
| 2024-07-23 | 2.33 | 2.35 | +0.68% |
| 2024-04-23 | 1.86 | 2.04 | +9.75% |
| 2024-02-01 | 2.11 | 2.15 | +1.68% |
| 2023-10-24 | 2.19 | 2.22 | +1.40% |
| 2023-07-26 | 2.26 | 2.30 | +1.87% |
| 2023-04-27 | 1.97 | 2.04 | +3.53% |
| 2023-02-02 | 1.90 | 1.98 | +3.97% |
| 2022-10-20 | 2.19 | 2.36 | +7.57% |